用于卵巢癌化疗-光热联合治疗的吉西他滨/聚吡咯复合纳米粒子

利用铁离子诱发吡咯氧化聚合反应制备了尺寸均一的聚吡咯纳米粒子, 并进一步负载化疗药物吉西他滨, 得到了吉西他滨/聚吡咯复合纳米粒子. 该复合纳米粒子对吉西他滨的负载能力强, 在水溶液中的稳定性好, 有助于降低吉西他滨对正常组织的毒副作用. 此外, 该复合纳米粒子在近红外光区有较强的吸收, 能够将吸收的光能转化为热, 是一种良好的光热试剂, 具有光热治疗功能. 同时, 该复合纳米粒子能够在热刺激下释放吉西他滨, 具有光热介导的化疗功能. 因此, 吉西他滨/聚吡咯复合纳米粒子是一种兼具化疗和光热治疗功能的联合治疗试剂. 复合纳米粒子在808 nm近红外激光照射下能够快速提升系统温度, 实现光热治疗与化疗联合杀伤卵巢癌细胞, 具有良好的生物医学应用潜力.

Gemcitabine/polypyrrole Composite Nanoparticles for Chemo-photothermal Combination Ovarian Cancer Therapy

Polypyrrole nanoparticles（NPs） were prepared through iron ion-induced oxidative poly?merization and employed for loading chemotherapy drug gemcitabine， thus producing gemcitabine/polypyrrole composite NPs. The composite NPs indicate strong loading capacity for gemcitabine and good stability in aqueous solution， which reduces the toxicity and side effects of gemcitabine on normal tissues. In addition， the composite NPs have strong absorption in the near-infrared region and can transform the absorbed light energy into heat， acting as an efficient photothermal reagent for tumor photothermal therapy. Meanwhile， the composite NPs are capable to release gemcitabine and perform photothermal-guided chemotherapy. As the reagent with chemo-photothermal combination therapeutic efficacy， gemcitabine/polypyrrole composite NPs can ablate ovarian cancer cells under near-infrared laser irradiation， showing the potential for ovarian cancer therapy.